Evidence-based oncology for trainees from LMICs

Dihydropyrimidine dehydrogenase polymorphisms knocking on the door

Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Post-HSCT management of ALL - Adult ALL perspective

Latest in diagnostics in EGFR mutated NSCLC

The Lancet Commission on women and cancer

Cancer drug policy and access in LMICs